Tate & Lyle (TATE) CMD 2025 summary

Strategic transformation and business positioning

• Completed transformation into a specialty food and beverage solutions business, integrating CP Kelco and shifting away from commodities to focus on sweetening, mouthfeel, and fortification platforms, with a broad ingredient portfolio and enhanced technical capabilities.

• Portfolio now includes over 1,000 ingredients, with market-leading positions in sugar reduction, mouthfeel (via pectins, gums, starches), and dietary fiber fortification, supported by four strategic acquisitions since 2018.

• Purpose-driven and science-led, the company aims to address global food and health challenges through reformulation, innovation, and supporting healthy living, thriving communities, and environmental care.

• CP Kelco integration brings unique technical capabilities, expanded customer access, and a leadership position in mouthfeel, especially in fast-growing markets, with 1/3 of directly-served customers new to the group.

• Achieved significant societal impact, removing 40 trillion calories from diets, donating 4.6 million meals, and reducing Scope 3 GHG emissions by 31% since 2019.

Financial guidance and growth outlook

• Targets organic revenue growth at the higher end of 4%-6% per year, with EBITDA and EPS growth ahead of revenue, supported by operational leverage, cost synergies, and a disciplined capital allocation strategy prioritizing organic growth, M&A, and shareholder returns.

• Specialty business generates over GBP 2.1 billion in revenue and GBP 400 million in EBITDA, with a 21% EBITDA margin, benchmarking well against peers and improving from 17.4% in 2020.

• Free cash flow conversion expected to exceed 75%, with net debt to EBITDA targeted between 1.0x and 2.5x.

• CP Kelco integration is on track, with $25 million in run-rate cost synergies expected this year, a total target of $50 million by end of 2027, and 10% revenue synergies over the medium term.

• CapEx intensity is expected at 6%-7% of revenue through 2027-2028, with growth projects targeting at least a 20% IRR.

Innovation, customer solutions, and market opportunities

• Investment in R&D and innovation exceeds $370 million, with nearly 1,000 patents, 63 new products launched from 2020–2025, and the ALFIE automated lab accelerating ingredient development.

• The combined portfolio enables unique solutions in reformulation, optimizing taste, texture, and nutrition, with a focus on healthier, cleaner-label, and sustainable products.

• Expanded global network of 21 innovation and customer collaboration centers, with over 70% in fast-growing markets, prioritizing customer intimacy and solution selling.

• Early cross-selling wins and a growing pipeline are evident, especially in Asia and dairy, with direct customer engagement accelerating post-integration and synergy realization supported by cross-selling and consolidated distribution.

• Addressable market for its three platforms is approximately US$20 billion, with substantial opportunity in sugar replacement and fiber-based solutions.